Innovative Therapeutics in Oncology and Neuroscience
8
Driving Topline Growth Through Strong Commercial Execution
Demonstrated Proven Commercial Capabilities
Leveraging NRDL...
Once-daily oral
Zejula
niraparib
capsules 100 mg
#1 share in PARPI OC
hospital sales in China¹
Share in PARPI
45%
hospital sales in China
across all indications1
Significant Potential for VVVGART
VYVGARTⓇ
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial
Covered by NRDL (~$800 / vial)
Huge Unmet Need in China
...and supplemental insurance plan (SIP)
Pipeline-in-a-product
XOPTUNE
TOP
GIO™
2
Reimbursed in SIP
only after Keytruda;
top 1 for Shanghai and
Beijing²
NRDL Price Reflects High Clinical Value
Notes: The trademarks and registered trademarks within are the property of their respective owners. (1) Based on 4Q 2023 quarterly data from IQVIA Hospital Audit (>=100 beds), December 2023. "Share in PARPI" refers to hospital sales in value
in China per IQVIA analysis; (2) Based on 4Q 2023 data, Meditrust Health disclosure.
zaiLǝbView entire presentation